Ngumi P N, Young A S, Lampard D, Mining S K, Ndungu S G, Lesan A C, Williamson S M, Linyonyi A, Kariuki D P
Protozoology Division, National Veterinary Research Centre, Muguga, Kenya.
Vet Parasitol. 1992 Jun;43(1-2):15-24. doi: 10.1016/0304-4017(92)90044-a.
Three experiments were undertaken to determine the efficacy of different doses of buparvaquone in the infection and treatment immunization of cattle against Theileria parva derived from African buffalo (Syncerus caffer). Two of these experiments also compared buparvaquone with standard doses of long- and short-acting formulations of oxytetracycline. In addition, different dilutions of stabilates were used in the experiments. In the first experiment, a 10(-1.0) dilution of stabilate was used to infect groups of cattle treated with buparvaquone at doses of between 5 and 0.625 mg kg-1 body weight (bwt) on Day 0 after infection. All control cattle developed severe theileriosis and none of the treatment regimes (including those utilizing long-acting oxytetracycline) prevented the development of theileriosis. Treatment with buparvaquone at 2.5 mg kg-1 bwt or oxytetracycline gave the most satisfactory results. In the second experiment when the sporozoite dose was reduced to 10(-2.0) dilution, buparvaquone treatment at 5 and 2.5 mg kg-1 bwt and short- and long-acting formulations of oxytetracycline reduced reactions greatly. While all the oxytetracycline treated animals produced a serological response and were immune to a 50-fold higher challenge with the immunizing stabilate, several animals in the buparvaquone groups did not show a serological response and were not immune to challenge. In the third experiment, groups of cattle were infected with 10(-1.2), 10(-1.4) and 10(-1.6) dilutions of stabilate and were treated with 2.5 mg kg-1 bwt of buparvaquone. No animals developed severe theileriosis and all seroconverted. On homologous challenge, however, two out of 14 cattle showed severe reactions. It was concluded that further work on immunization using buparvaquone treatment at 2.5 mg kg-1 bwt and 10(-1.6) dilution of the stabilate would have to be carried out before such a system could be used in the field.
进行了三项实验,以确定不同剂量的布帕伐醌在牛感染及治疗免疫中抵御源自非洲水牛(非洲野水牛)的泰勒虫的效果。其中两项实验还将布帕伐醌与标准剂量的长效和短效土霉素制剂进行了比较。此外,实验中使用了不同稀释度的冻存株。在第一项实验中,使用10(-1.0)稀释度的冻存株感染牛群,并在感染后第0天给牛群按5至0.625毫克/千克体重(bwt)的剂量注射布帕伐醌进行治疗。所有对照牛都患上了严重的泰勒虫病,且没有任何一种治疗方案(包括使用长效土霉素的方案)能预防泰勒虫病的发生。按2.5毫克/千克体重(bwt)的剂量注射布帕伐醌或土霉素的治疗效果最为理想。在第二项实验中,当子孢子剂量降至10(-2.0)稀释度时,按5和2.5毫克/千克体重(bwt)的剂量注射布帕伐醌以及使用长效和短效土霉素制剂极大地减轻了反应。虽然所有接受土霉素治疗的动物都产生了血清学反应,并且对用免疫冻存株进行的50倍高剂量攻击具有免疫力,但布帕伐醌组中的几只动物并未表现出血清学反应,且对攻击没有免疫力。在第三项实验中,用10(-1.2)、10(-1.4)和10(-1.6)稀释度的冻存株感染牛群,并按2.5毫克/千克体重(bwt)的剂量给牛群注射布帕伐醌。没有动物患上严重的泰勒虫病,且所有动物都发生了血清转化。然而,在同源攻击时,14头牛中有两头出现了严重反应。得出的结论是,在该系统能够用于实地之前,必须进一步开展关于使用2.5毫克/千克体重(bwt)的布帕伐醌治疗和10(-1.6)稀释度的冻存株进行免疫的研究。